Zura Bio Limited (NASDAQ:ZURA) Director Sells $200,187.36 in Stock

Zura Bio Limited (NASDAQ:ZURA) Director Someit Sidhu sold 51,728 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total transaction of $200,187.36. Following the completion of the sale, the director now directly owns 2,085,418 shares of the company’s stock, valued at approximately $8,070,567.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Zura Bio Trading Down 4.0 %

ZURA traded down $0.15 during trading on Friday, hitting $3.62. 183,836 shares of the stock traded hands, compared to its average volume of 280,554. The firm has a 50-day moving average of $3.69 and a 200 day moving average of $3.77. Zura Bio Limited has a 12-month low of $2.00 and a 12-month high of $7.22.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Tuesday, August 13th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). On average, research analysts anticipate that Zura Bio Limited will post -0.53 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ZURA. AQR Capital Management LLC bought a new stake in shares of Zura Bio in the second quarter valued at about $43,000. Renaissance Technologies LLC raised its stake in Zura Bio by 51.3% in the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after purchasing an additional 5,900 shares during the last quarter. Forefront Analytics LLC grew its holdings in shares of Zura Bio by 46.8% in the fourth quarter. Forefront Analytics LLC now owns 21,229 shares of the company’s stock valued at $99,000 after purchasing an additional 6,765 shares during the period. Bank of New York Mellon Corp boosted its stake in Zura Bio by 15.8% during the second quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock worth $165,000 after buying an additional 6,412 shares during the period. Finally, Affinity Asset Advisors LLC purchased a new stake in Zura Bio during the first quarter worth about $1,157,000. Institutional investors own 61.14% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on ZURA shares. HC Wainwright assumed coverage on shares of Zura Bio in a report on Thursday. They issued a “neutral” rating and a $5.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a report on Thursday, August 15th. Finally, Oppenheimer upped their price objective on Zura Bio from $16.00 to $21.00 and gave the company an “outperform” rating in a research note on Friday, May 10th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $15.50.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.